December 6th 2024
BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.
November 14th 2024
Study: Dry eye disease alters how the eye’s cornea heals itself after injury
January 3rd 2023Researchers at Washington University School of Medicine in St. Louis have found that proteins made by stem cells that regenerate the cornea may be new targets for treating and preventing such injuries.
Read More
OC-01 0.03 mg nasal spray is effective against dry eye disease regardless of menopausal status
November 29th 2022According to investigators, the risk for the development of dry eye disease is greater in postmenopausal women compared with those who have not reached menopause as a result of hormonal dysregulation of the ocular secretory glands.
Read More
Bausch + Lomb, Novaliq announce U.S. FDA filing acceptance for investigational treatment NOV03
September 6th 2022A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.
Read More
Tarsus initiates Phase 2a ERSA trial evaluating TP-03 for treatment of meibomian gland disease
August 5th 2022Tarsus Pharmaceuticals has enrolled the first patient in a Phase 2a clinical trial studying TP-03 for the treatment of meibomian gland disease in patients diagnosed with Demodex mites.
Read More
TearSolutions planning Phase II/III trials for therapy to treat dry eye disease
February 25th 2022TearSolutions Inc. is preparing to conduct two trials, one in a primary Sjögren’s Syndrome patient population and the second in a potentially less severe general dry eye population for the treatment of DED.
Read More
Researchers pioneer technology that leads successful clinical trial to treat dry eye disease
October 4th 2021A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.
Read More
Smartphone screening and referral increases access to care for people with eye problems
June 22nd 2021According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.
Read More
Stuart Therapeutics begins patient enrollment in Phase 2 study of dry eye disease therapeutic option
June 11th 2021Stuart will enroll 150 volunteers in the study, which is being conducted with the support of Stuart's strategic partner and CRO, Ora Clinical. ST-100 is based on PolyCol, the company's synthesized polypeptide tissue reparative platform.
Read More